secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ventyx Biosciences, Inc. (—)
CIK:        0001851194
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-006520
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eli Lilly to acquire Ventyx Biosciences for $14.00 per share (~$1.2B equity value)
--------------------------------------------------------------------------------

- All-cash deal at $14.00/share; aggregate equity value of ~$1.2 billion.
- Premium of ~62% to 30-day volume-weighted average price as of Jan 5, 2026.
- Closing expected first half of 2026; subject to stockholder approval and regulatory clearance.
- Directors, officers, and New Science Ventures (10% of shares) signed voting agreements to support.
- Ventyx pipeline includes oral NLRP3 inhibitors for cardiometabolic, neurodegenerative, and autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851194/000119312526006520/0001193125-26-006520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851194/000119312526006520/d98679d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer